Related Experiment Video
Updated: Aug 9, 2026
11:45
Quantifying Agonist Activity at G Protein-coupled Receptors
Published on: December 26, 2011
Structure-activity studies with histamine H3-receptor ligands
C R Ganellin1, A Fkyerat, S K Hosseini
1Department of Chemistry, Christopher Ingold Laboratories, University College, London, UK.
Journal De Pharmacie De Belgique
|March 1, 1995
Summary
Researchers synthesized novel histamine H3 receptor antagonists, moving beyond thioperamide. New compounds show potent activity and improved brain penetration, offering potential therapeutic advancements.
Area of Science:
- Medicinal Chemistry
- Neuropharmacology
- Histamine Receptor Research
Background:
- Thioperamide was the first potent and selective histamine H3-receptor antagonist.
- Developing new H3 receptor antagonists with improved properties is a key research area.
Purpose of the Study:
- To synthesize and test analogues of thioperamide to explore structure-activity relationships.
- To design compounds without the thiourea group for potentially enhanced brain penetration.
- To identify potent H3 receptor antagonists with potential therapeutic applications.
Main Methods:
- In vitro testing of synthesized analogues on rat cerebral cortex.
- Structure-activity relationship (SAR) studies.
- Synthesis of novel imidazole derivatives and isothioureas.
Main Results:
- Compounds derived from histamine with aromatic nitrogen-containing heterocycles exhibited strong H3 antagonist activity.
- Aryloxyethyl- and aryloxy-propylimidazoles were identified as potent H3 antagonists.
- Structure-activity studies revealed potent agonists and antagonists, including N,N'-Dibutyl-[S-[3-(imidazol-4-yl)propyl]isothiourea with Ki = 1.5 nM.
Conclusions:
- Novel H3 receptor antagonists have been successfully designed and synthesized.
- The developed compounds demonstrate potent H3 antagonist activity and potential for improved brain penetration.
- These findings contribute to the development of new therapeutic agents targeting the H3 receptor.
Related Concept Videos
01:22Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
01:29Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...